Healthcare Industry News: vigabatrin
News Release - August 20, 2008
Biovail Appoints Dr. Neil M. Sussman Vice-President, Neurologic & Psychiatric DevelopmentTORONTO--(HSMN NewsFeed)--Biovail Corporation (NYSE:BVF )(TSX:BVF ) today announced the appointment of Dr. Neil M. Sussman as Vice-President, Neurologic and Psychiatric Development of Biovail Technologies, Ltd. The appointment is effective immediately.
Dr. Sussman brings a wealth of business and academic experience in the field of neurology and other central nervous system (CNS) disorders to Biovail.
“We are delighted to have an individual as qualified as Dr. Sussman join our Medical and Scientific Affairs team,” said Bill Wells, Biovail’s Chief Executive Officer. “The addition of his expertise and experience in CNS disorders is an important step in the implementation of Biovail’s New Strategic Focus.”
Prior to joining Biovail, Dr. Sussman was President of NMSNeuro Consulting, specializing in therapeutic areas such as dementia, mania, neuroprotection, multiple sclerosis and Parkinson’s disease. Before that, Dr. Sussman was Senior Director, CNS Clinical Research of Kyowa Pharmaceutical, overseeing development-stage products in Parkinson’s disease. Earlier in his career, Dr. Sussman held positions of increasing responsibly at Marion Merrell Dow where he worked on the development of vigabatrin (Sabril); Abbott Laboratories, where he served as Venture Head, Neurotherapeutics; Bristol-Myers Squibb’s CNS Clinical Research division; and Forest Laboratories, as Director, CNS Clinical Development, where he was involved in the development of escitalopram (Lexapro). He also spent four years as Director, Medical Affairs with PRA International, a global clinical research (CRO) organization.
Dr. Sussman received his medical training at New York Medical College and completed his Neurology Residency at Thomas Jefferson University in Philadelphia. His post-graduate training includes Fellowships in Neurology, and Epilepsy and Electroencephalography. He is certified by the American Board of Psychiatry and Neurology, and was on the faculty of the Department of Neurology at the University of Pennsylvania, Medical College of Pennsylvania and Yale University School of Medicine, and he is a Fellow in the American Academy of Neurology. Dr. Sussman has co-authored over 30 peer-reviewed original papers in the area of CNS disorders. His knowledge, energy and extensive network should facilitate Biovail’s future drug-development success.
About Biovail Corporation
Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company’s Web site at www.biovail.com.
For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to email@example.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.